A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies

NCT07887867 | Not Yet Recruiting

• 2 other identifiers: B7451138ABRO-SWITCH
• Study Type: observational
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this observational study is to learn about the effects of the study medicine (called abrocitinib) for the treatment of severe atopic dermatitis in people that were moved from previous novel therapies, known as "advanced" therapies. Atopic dermatitis is a long-lasting skin condition that causes the skin to become inflamed, dry, and itchy. This study is seeking participants who:

• are 18 years of age or older;
• have severe atopic dermatitis;
• have previously been treated with advanced therapies authorised for atopic dermatitis and are moving to abrocitinib (100 mg or 200 mg);
• have received no more than two authorised advanced therapies for their atopic dermatitis. All participants will receive study medicine, abrocitinib as part of their usual medical care. The decision to give the study medicine is made by their dermatologist. This decision is independent of participation in the study. Abrocitinib will be taken by mouth at home once daily as prescribed by the treating doctor. We will examine the experiences of people receiving abrocitinib for up to one year after starting abrocitinib. We will look back at the information up to 6 months before they have started taking abrocitinib. This will help us learn how abrocitinib affects severe atopic dermatitis in people who have moved from other authorised advanced therapies. Participants will take part in this study for 1 year. During this time, they will have about 5 visits. These visits are a part of their routine care. During the visits, the doctor will assess how severe atopic dermatitis is. Participants may be asked questions about their symptoms and how the condition affects their daily life. No additional clinic visits, tests, or procedures are required for this study, beyond normal clinical practice.

Conditions

Dermatitis, Atopic

Keywords

Dermatitis, Atopic; Abrocitinib; Janus Kinase Inhibitors; Pruritus; Quality of Life; Treatment Switching; Real-World Evidence

Outcome Measures

Primary Outcomes (1)

• Percentage of Participants Achieving Eczema Area and Severity Index (EASI) <7

  Week 24

Secondary Outcomes (19)

• EASI 90

  Week 4, 12, 24, 52

• Change from baseline in Eczema Area and Severity Index (EASI) Score

  Baseline, Week 4, 12, 24, 52

• Change from baseline in Peak Pruritus-Numeric Rating Scale (PP-NRS) Score

  Baseline, Week 4, 12, 24, 52

• Percentage of Participants Achieving PP-NRS <=1

  Week 4, 12, 24, 52

• Change from baseline in Investigator's Global Assessment (IGA) Score

  Week 4, 12, 24, 52

Study Arms (1)

Patients switched to abrocitinib

Adult patients with severe atopic dermatitis who switched from previous advanced therapies (dupilumab, lebrikizumab, tralokinumab, baricitinib, upadacitinib) to abrocitinib according to routine clinical practice

Drug: abrocitinib

Interventions

abrocitinib DRUG

Abrocitinib administered according to routine clinical practice at doses of 100 mg or 200 mg once daily.

Patients switched to abrocitinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

severe atopic dermatitis adult (\>=18 years) patients of both sexes who, according to clinical practice, have been switched directly to abrocitinib 100 mg or 200 mg after a maximum of 2 previous advanced therapies for the treatment of severe atopic dermatitis, including biologics (i.e., dupilumab, lebrikizumab, tralokinumab) and/or JAKis (i.e., baricitinib, upadacitinib).

You may qualify if:

• \>=18 years of age on date of the enrolment visit
• Severe atopic dermatitis diagnosed in accordance with guidelines used per clinical practice
• Patients have agreed to switch from a prior advanced therapy for severe AD (i.e., dupilumab, lebrikizumab, tralokinumab, baricitinib, or upadacitinib) to abrocitinib 100 mg or 200 mg, based on the Investigator's clinical judgment and independent of study participation.
• Evidence of a personally signed and dated informed consent document

Sponsors & Collaborators

• Pfizer: lead

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Dermatitis, Atopic; Dermatitis; Pruritus

Interventions

abrocitinib

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Central Study Contacts

Pfizer CT.gov Call Center

CONTACT

1-800-718-1021; ClinicalTrials.gov_Inquiries@pfizer.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 29, 2026
• First Posted: October 21, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): August 31, 2028
• Last Updated: October 21, 2026

Record last verified: 2026-10

Data Sharing

• IPD Sharing: Will not share